



The ethics committee in London gives approval to start clinical study

As previously announced, SpectraCure has received approval from Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to conduct parts of the ongoing Phase 1 clinical trial for the treatment of prostate cancer in London. Now, also the regional ethics committee in London has approved the study protocol. This means that all formal requirements are met, and the study can begin in London at University College London Hospital.

The study is the same Phase 1-study that SpectraCure is conducting for the treatment of prostate cancer at Princess Margaret Cancer Centre in Toronto, Canada

The treatment method evaluated in the study, called photodynamic therapy (PDT), means that the patient is given a light-activated drug that accumulates in the tumour. When the cancer tissue is illuminated by laser light of a certain wavelength, the drug is activated and destroys out the tumor. The target group of the study is patients who have recurrent prostate cancer after having had radiotherapy.

For further information, please contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on April 10th, 2018.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region